Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.

Current treatment options in oncology - 29 Jul 2026

Ibrahim Rebecca, Vibert Julien, Moussa Tania, Ngo Carine, Faron Matthieu, Verret Benjamin, Zanella Caterina, Mikhael Rabih, Tabet Elie, Lévy Antonin, Honoré Charles, Le Péchoux Cécile, Bahleda Ratislav, Le Cesne Axel, Assi Tarek

Abstract excerpt

OPINION STATEMENT: Dedifferentiated chondrosarcoma (DDCS) remains one of the most aggressive and therapeutically challenging primary bone malignancies. While surgery continues to represent the cornerstone of treatment for localized disease, outcomes remain poor due to high rates of local recurrence and metastatic progression. The role of adjuvant therapies remains less clear. Radiotherapy may be considered in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chondrosarcoma

Share to Combined Modality Therapy

Share to Disease Management

Share to Immunotherapy

Share to Isocitrate Dehydrogenase

Share to Molecular Targeted Therapy

Source

Identifiers

PMID: 42525308
DOI: 10.1007/s11864-026-01407-y

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.PMID 42525308Read ↗

Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets.Semantic proximity Read ↗

Dedifferentiated chondrosarcoma: current standards of care.Semantic proximity Read ↗

Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.Semantic proximity Read ↗

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.Semantic proximity Read ↗

Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic TargetsSemantic proximity Read ↗

Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to ImmunophenotypeSemantic proximity Read ↗

Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision MedicineSemantic proximity Read ↗

Chondrosarcoma: biology, genetics, and epigeneticsSemantic proximity Read ↗

Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation.Semantic proximity Read ↗

Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.Semantic proximity Read ↗

Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targetsSemantic proximity Read ↗

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.